Citations (138)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
P.A. Mataranyika, D. Kibuule, F. Kalemeera, H. Kaura, B. Godman & T.W. Rennie. (2018) Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: Findings and implications. Alexandria Journal of Medicine 54:1, pages 49-56.
Read now
Read now
Nisha Andany, V Logan Kennedy, Muna Aden & Mona Loutfy. (2016) Perspectives on menopause and women with HIV. International Journal of Women's Health 8, pages 1-22.
Read now
Read now
Philip M. Grant, Douglas Kitch, Grace A. McComsey, Camlin Tierney, Belinda Ha & Todd T. Brown. (2015) Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults. HIV Clinical Trials 16:2, pages 66-71.
Read now
Read now
Jonathan Winston, Michel Chonchol, Joel Gallant, Jacques Durr, Robert B. Canada, Hui Liu, Patty Martin, Kiran Patel, Jason Hindman & David Piontkowsky. (2014) Discontinuation of Tenofovir Disoproxil Fumarate for Presumed Renal Adverse Events in Treatment-Naïve HIV-1 Patients: Meta-analysis of Randomized Clinical Studies. HIV Clinical Trials 15:6, pages 231-245.
Read now
Read now
Willem De Lange, Jan-Loot Pretorius, Daleen Oosthuizen & Gerda Marx. (2014) HIV/AIDS and bone: an unrecognised threat?. South African Family Practice 56:6, pages 326-329.
Read now
Read now
Kathleen Ferrer & Natella Rakhmanina. (2013) Neuropsychiatric effects of tenofovir in comparison with other antiretroviral drugs. Neurobehavioral HIV Medicine 5, pages 1-10.
Read now
Read now
Jeannie S. Huang, Michael D. Hughes, Sharon A. Riddler & Richard H. Haubrich. (2013) Bone Mineral Density Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor Selection from ACTG A5142. HIV Clinical Trials 14:5, pages 224-234.
Read now
Read now
Gabriel Rebick & Sharon L Walmsley. (2012) Issues in resistance, adherence, and comparative efficacy of the single-tablet regimen combination of tenofovir, emtricitabine, and efavirenz in the management of HIV-1 infection. Virus Adaptation and Treatment 4, pages 51-63.
Read now
Read now
Maria Gracia Mateo, Maria del Mar Gutierrez, Francesc Vidal & Pere Domingo. (2012) Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection. Expert Opinion on Drug Safety 11:3, pages 473-485.
Read now
Read now
Maxwell O Akanbi, Kimberly Scarsi, Babafemi Taiwo & Robert L Murphy. (2012) Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection. Expert Opinion on Pharmacotherapy 13:1, pages 65-79.
Read now
Read now
Elena Alvarez, Judit Morello, Vincent Soriano, Pablo Labarga & Sonia Rodriguez-Nóvoa. (2011) Critical appraisal and update on tenofovir in management of human immunodeficiency virus infection. Virus Adaptation and Treatment 3, pages 55-69.
Read now
Read now
Michael A Horberg & Daniel B Klein. (2010) An update on the use of Atripla® in the treatment of HIV in the United States. HIV/AIDS - Research and Palliative Care 2, pages 135-140.
Read now
Read now
Richard Elion, Calvin Cohen, Douglas Ward, Peter Ruane, Roberto Ortiz, Y. Sunila Reddy, Ramin Ebrahimi, Damian McColl, Brian Kearney, Alvan Fisher & John Flaherty. (2008) Evaluation of Efficacy, Safety, Pharmacokinetics, and Adherence in HIV-1—Infected, Antiretroviral-Naïve Patients Treated with Ritonavir-Boosted Atazanavir Plus Fixed-Dose Tenofovir DF/Emtricitabine Given Once Daily. HIV Clinical Trials 9:4, pages 213-224.
Read now
Read now
Christoph Stephan. (2008) Experience with tenofovir disoproxil fumarate for antiretroviral therapy. Expert Opinion on Pharmacotherapy 9:7, pages 1197-1209.
Read now
Read now
Edwin DeJesus, Peter Ruane, Cheryl McDonald, Fernando Garcia, Shetal Sharma, Roberto Corales, Jayashree Ravishankar, Homayoun Khanlou, David Shamblaw, Janet Ecker, Ramin Ebrahimi & John Flaherty. (2008) Impact of Switching Virologically Suppressed, HIV-1-Infected Patients from Twice-Daily Fixed-Dose Zidovudine/Lamivudine to Once-Daily Fixed-Dose Tenofovir Disoproxil Fumarate/Emtricitabine. HIV Clinical Trials 9:2, pages 103-114.
Read now
Read now
Saba Woldemichael Masho, Cun-Lin Wang & Daniel E Nixon. (2007) Review of tenofovir-emtricitabine. Therapeutics and Clinical Risk Management 3:6, pages 1097-1104.
Read now
Read now
José V.R. Madruga, Isabel Cassetti, Jamal Muhamad A.H. Suleiman, Arnaldo Etzel, Lijie Zhong, Charles B. Holmes, Andrew K. Cheng & Jeffrey Enejosa. (2007) The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1—Infected Patients: Three-Year Follow–up After Switching Therapy. HIV Clinical Trials 8:6, pages 381-390.
Read now
Read now
Articles from other publishers (121)
Eunju Kim, Hyun Woong Lee, Soon Sun Kim, Eileen Yoon, Eun Sun Jang, Jong‐In Chang, Young Youn Cho, Gi Hyeon Seo & Hyung Joon Kim. (2023) Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea. Alimentary Pharmacology & Therapeutics 58:11-12, pages 1185-1193.
Crossref
Crossref
Lalita Wattanachanya, Sarat Sunthornyothin, Tanakorn Apornpong, Hay Mar Su Lwin, Stephen Kerr, Sivaporn Gatechompol, Win Min Han, Thanathip Wichiansan, Sarawut Siwamongsatham, Pairoj Chattranukulchai, Tawatchai Chaiwatanarat & Anchalee Avihingsanon. (2022) Bone mineral density among virologically suppressed Asians older than 50 years old living with and without HIV: A cross-sectional study. PLOS ONE 17:11, pages e0277231.
Crossref
Crossref
Simon M. Graham, Murtadhah M. K. Jalal, David G. Lalloo & A. Hamish R. W. Simpson. (2022) The effect of anti-retroviral therapy on fracture healing. Bone & Joint Research 11:8, pages 585-593.
Crossref
Crossref
Ramakrishna Narra, Sravan Kumar Varra & Naganarasimha Raju Jukuri. (2022) Bilateral symmetrical stress fractures of femoral neck in HIV patient: case report and brief review of literature. BJR|case reports.
Crossref
Crossref
Zhihong Liu, Qinglong Jin, Yuexin Zhang, Guozhong Gong, Guicheng Wu, Lvfeng Yao, Xiaofeng Wen, Zhiliang Gao, Yan Huang, Daokun Yang, Enqiang Chen, Qing Mao, Shide Lin, Jia Shang, Huanyu Gong, Lihua Zhong, Huafa Yin, Fengmei Wang, Peng Hu, Ling Xiao, Chuan Li, Qiong Wu, Chang’an Sun, Junqi Niu & Jinlin Hou. (2021) Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics 54:9, pages 1134-1149.
Crossref
Crossref
Jane C Lindsey, Denise L Jacobson, Hans M Spiegel, Catherine M Gordon, Rohan Hazra & George K Siberry. (2021) Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age. Clinical Infectious Diseases 72:6, pages 1059-1063.
Crossref
Crossref
Dionna W. Williams, Yuliang Li, Raha Dastgheyb, Kathryn C. Fitzgerald, Pauline M. Maki, Amanda B. Spence, Deborah R. Gustafson, Joel Milam, Anjali Sharma, Adaora A. Adimora, Igho Ofotokun, Margaret A. Fischl, Deborah Konkle-Parker, Kathleen M. Weber, Yanxun Xu & Leah H. Rubin. (2020) Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV. Journal of Neuroimmune Pharmacology 16:1, pages 181-194.
Crossref
Crossref
Erisa Sabakaki Mwaka, Ian Guyton Munabi, Barbara Castelnuovo, Arvind Kaimal, William Kasozi, Andrew Kambugu, Philippa Musoke & Elly Katabira. (2021) Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda. PLOS ONE 16:2, pages e0246389.
Crossref
Crossref
Yvonne A. Scriven, Martin M. Mulinge, Norah Saleri, Elizabeth A. Luvai, Atunga Nyachieo, Esther N. Maina & Matilu Mwau. (2021) Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya. Medicine 100:40, pages e27460.
Crossref
Crossref
Xiaowei He, Cheng Xu, Zheng-Hong Lu, Xiao-Zheng Fang, Juan Tan & Yingjian Song. (2020) Low serum 25-hydroxyvitamin D levels are associated with liver injury markers in the US adult population. Public Health Nutrition 23:16, pages 2915-2922.
Crossref
Crossref
Denise L Jacobson, Jane C Lindsey, Catherine Gordon, Rohan Hazra, Hans Spiegel, Flavia Ferreira, Fabiana R Amaral, Jesica Pagano-Therrien, Aditya Gaur, Kathy George, Jane Benson & George K Siberry. (2020) Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age. Clinical Infectious Diseases 71:5, pages 1281-1288.
Crossref
Crossref
Rong Chen, Jun Chen, Jingna Xun, Zhiliang Hu, Qiong Huang, Renfang Zhang, Corky Steinhart, Yinzhong Shen, Li Liu & Hongzhou Lu. (2020) Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China. Pharmacogenomics 21:13, pages 945-956.
Crossref
Crossref
Bryna J. Harrington, Bethany L. DiPrete, Allan N. Jumbe, McNeil Ngongondo, Laura Limarzi, Shaphil D. Wallie, Maganizo B. Chagomerana & Mina C. Hosseinipour. (2019) Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz. Tropical Medicine & International Health 24:10, pages 1221-1228.
Crossref
Crossref
Mark J. Bolland, Anne M. Horne, Simon E. Briggs, Mark G. Thomas, Ian R. Reid, Greg D. Gamble & Andrew Grey. (2019) Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. Calcified Tissue International 105:4, pages 423-429.
Crossref
Crossref
Joo Zheng Low, Su Pei Khoo, Nuruljannah Nor Azmi, Meng Li Chong, Helmi Sulaiman, Iskandar Azwa, Ching Hooi Tan, Adeeba Kamarulzaman & Reena Rajasuriar. (2018) Is the risk of tenofovir‐induced nephrotoxicity similar in treatment‐naïve compared to treatment‐experienced patients?. Journal of Pharmacy Practice and Research 48:3, pages 242-250.
Crossref
Crossref
Rongfeng Chen, Bingyu Liang, Binbin Wen, Guanghua Huang, Chuanyi Ning, Chengyong Lao, Junjun Jiang, Jie Liu, Bo Zhou, Jiegang Huang, Jinmei Chen, Ning Zang, Yanyan Liao, Dongsong Mo, Li Ye & Hao Liang. (2018) No Difference in Prevalence of Transmitted Drug Resistance between Injection Drug Users and Non-Injection Drug Users: A Cross-Sectional Study among Antiretroviral Treatment-Naïve HIV Patients. Intervirology 61:6, pages 281-291.
Crossref
Crossref
Onyemaechi O. Azu & Edwin C.S. Naidu. 2018. HIV/AIDS. HIV/AIDS
219
238
.
S Gallien, V Journot, M-A Loriot, H Sauvageon, P Morlat, J Reynes, V Reliquet, G Chêne & J-M Molina. (2017) Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial. HIV Medicine 18:8, pages 537-545.
Crossref
Crossref
Vania Giacomet, Katia Maruca, Alessandro Ambrosi, Gian Vincenzo Zuccotti & Stefano Mora. (2017) A 10–year follow−up of bone mineral density in HIV−infected youths receiving tenofovir disoproxil fumarate. International Journal of Antimicrobial Agents 50:3, pages 365-370.
Crossref
Crossref
Jennifer F Hoy, Birgit Grund, Mollie Roediger, Ann V Schwartz, John Shepherd, Anchalee Avihingsanon, Sharlaa Badal-Faesen, Stephane de Wit, Simone Jacoby, Alberto La Rosa, Sanjay Pujari, Mauro Schechter, David White, Nicole Wyman Engen, Kristine Ensrud, Peer D Aagaard & Andrew Carr. (2017) Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. Journal of Bone and Mineral Research 32:9, pages 1945-1955.
Crossref
Crossref
Aamir N. Ahmad, Shahid N. Ahmad & Nafees Ahmad. (2017) HIV Infection and Bone Abnormalities. The Open Orthopaedics Journal 11:1, pages 777-784.
Crossref
Crossref
Dhiraj Abhyankar, Ashish Shedage, Milind Gole & Preeti Raut. (2016) Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study. International Journal of STD & AIDS 28:5, pages 491-498.
Crossref
Crossref
Fengdi Zhang, Li Liu, Meiyan Sun, Jianjun Sun & Hongzhou Lu. (2017) An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China. PLOS ONE 12:2, pages e0165110.
Crossref
Crossref
Luiz Eduardo Osorio, Maria Ines Boechat, Mark Mirochnick, Newton Kumwenda, Regis Kreitchmann, Lynda Emel, Jorge Pinto, Esau Joao, Breno Santos, Molly Swenson, Kathleen George, Paul Sato, Lynne Mofenson & Karin Nielsen-Saines. (2017) Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057. Pediatric Infectious Disease Journal 36:2, pages 184-188.
Crossref
Crossref
Emmanuel Biver, Alexandra Calmy & René Rizzoli. (2016) Bone health in HIV and hepatitis B or C infections. Therapeutic Advances in Musculoskeletal Disease 9:1, pages 22-34.
Crossref
Crossref
S.E. Lazerwith, D. Siegel, R.M. McFadden, M.R. Mish & W.C. Tse. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
628
664
.
Maria Buti, Edward Gane, Wai Kay Seto, Henry L Y Chan, Wan-Long Chuang, Tatjana Stepanova, Aric-Josun Hui, Young-Suk Lim, Rajiv Mehta, Harry L A Janssen, Subrat K Acharya, John F Flaherty, Benedetta Massetto, Andrea L Cathcart, Kyungpil Kim, Anuj Gaggar, G Mani Subramanian, John G McHutchison, Calvin Q Pan, Maurizia Brunetto, Namiki Izumi & Patrick Marcellin. (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology & Hepatology 1:3, pages 196-206.
Crossref
Crossref
Henry L Y Chan, Scott Fung, Wai Kay Seto, Wan-Long Chuang, Chi-Yi Chen, Hyung Joon Kim, Aric Josun Hui, Harry L A Janssen, Abhijit Chowdhury, Tak Yin Owen Tsang, Rajiv Mehta, Edward Gane, John F Flaherty, Benedetta Massetto, Anuj Gaggar, Kathryn M Kitrinos, Lanjia Lin, G Mani Subramanian, John G McHutchison, Young-Suk Lim, Subrat K Acharya & Kosh Agarwal. (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology & Hepatology 1:3, pages 185-195.
Crossref
Crossref
J. Compston. (2016) HIV infection and bone disease. Journal of Internal Medicine 280:4, pages 350-358.
Crossref
Crossref
Brenda G. Mirembe, Clifton W. Kelly, Nyaradzo Mgodi, Susan Greenspan, James Y. Dai, Ashley Mayo, Jeanna Piper, Carolyne A. Akello, Flavia M. Kiweewa, Tsitsi Magure, Clemensia Nakabiito, Jeanne M. Marrazzo, Z. Mike Chirenje & Sharon A. Riddler. (2016) Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. JAIDS Journal of Acquired Immune Deficiency Syndromes 71:3, pages 287-294.
Crossref
Crossref
Donna E. Sweet, Frederick L. Altice, Calvin J. Cohen & Björn Vandewalle. (2016) Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLOS ONE 11:1, pages e0147821.
Crossref
Crossref
Stephen D. S. McCarthy, Beata Majchrzak-Kita, Trina Racine, Hannah N. Kozlowski, Darren P. Baker, Thomas Hoenen, Gary P. Kobinger, Eleanor N. Fish & Donald R. Branch. (2016) A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. PLOS Neglected Tropical Diseases 10:1, pages e0004364.
Crossref
Crossref
Marelize Swart, Jonathan Evans, Michelle Skelton, Sandra Castel, Lubbe Wiesner, Peter J. Smith & Collet Dandara. (2016) An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3′-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. Frontiers in Genetics 6.
Crossref
Crossref
. 2016. Molecular Microbiology. Molecular Microbiology
613
633
.
Mônica M. Bastos, Carolina C.P. Costa, Talitha C. Bezerra, Fernando de C. da Silva & Núbia Boechat. (2016) Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry. European Journal of Medicinal Chemistry 108, pages 455-465.
Crossref
Crossref
Tsung-Hui Hu & Chao-Long Chen. 2016. Hepatitis B Virus in Human Diseases. Hepatitis B Virus in Human Diseases
361
397
.
D. D. Byrne, C. W. Newcomb, D. M. Carbonari, M. S. Nezamzadeh, K. B. F. Leidl, M. Herlim, Y. X. Yang, S. Hennessy, J. R. Kostman, M. B. Leonard, A. R. Localio & V. Lo ReIIIIII. (2015) Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection. Journal of Viral Hepatitis 22:11, pages 936-947.
Crossref
Crossref
Anjali Sharma, Qiuhu Shi, Donald R. Hoover, Kathryn Anastos, Phyllis C. Tien, Mary A. Young, Mardge H. Cohen, Elizabeth T. Golub, Deborah Gustafson & Michael T. Yin. (2015) Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women. JAIDS Journal of Acquired Immune Deficiency Syndromes 70:1, pages 54-61.
Crossref
Crossref
Wissam K. Kabbara & Wijdan H. Ramadan. (2015) Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. Journal of Infection and Public Health 8:5, pages 409-417.
Crossref
Crossref
Kathleen Mulligan, David V. Glidden, Peter L. Anderson, Albert Liu, Vanessa McMahan, Pedro Gonzales, Maria Esther Ramirez-Cardich, Sirianong Namwongprom, Piotr Chodacki, Laura Maria Carvalo de Mendonca, Furong Wang, Javier R. Lama, Suwat Chariyalertsak, Juan Vicente Guanira, Susan Buchbinder, Linda-Gail Bekker, Mauro Schechter, Valdilea G. Veloso & Robert M. Grant. (2015) Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases 61:4, pages 572-580.
Crossref
Crossref
Anjali Sharma, Peter L. Flom, Clifford J. Rosen & Ellie E. Schoenbaum. (2015) Racial differences in bone loss and relation to menopause among HIV-infected and uninfected women. Bone 77, pages 24-30.
Crossref
Crossref
Tavitiya Sudjaritruk & Thanyawee Puthanakit. (2015) Adverse bone health among children and adolescents growing up with HIV. Journal of Virus Eradication 1:3, pages 159-167.
Crossref
Crossref
Andrew Ustianowski & Joop E. Arends. (2015) Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use. Infectious Diseases and Therapy 4:2, pages 145-157.
Crossref
Crossref
Linda Aurpibul & Thanyawee Puthanakit. (2015) Review of Tenofovir Use in HIV-infected Children. Pediatric Infectious Disease Journal 34:4, pages 383-391.
Crossref
Crossref
Juliet Compston. (2015) HIV infection and osteoporosis. BoneKEy Reports 4.
Crossref
Crossref
Graeme J. Moyle, Hélène Hardy, Awny Farajallah, St John McGrath, Stephen Kaplita & Douglas Ward. (2015) Changes in Bone Mineral Density After 96 Weeks of Treatment With Atazanavir/Ritonavir or Lopinavir/Ritonavir Plus Tenofovir DF/Emtricitabine in Treatment-Naive Patients With HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 68:1, pages 40-45.
Crossref
Crossref
Muhammad Imran Qadir, Muhammad Ali, Syed Aun Muhammad, Muhammad Hanif, Ammad Ahmad Farooqi & Ramsha Abbas. (2015) HIV-associated osteoporosis. Reviews in Medical Microbiology 26:1, pages 14-19.
Crossref
Crossref
Mark J Bolland, Andrew Grey & Ian R Reid. (2015) Skeletal health in adults with HIV infection. The Lancet Diabetes & Endocrinology 3:1, pages 63-74.
Crossref
Crossref
Maarten Danial & Harm‐Anton Klok. (2014) Polymeric Anti‐HIV Therapeutics. Macromolecular Bioscience 15:1, pages 9-35.
Crossref
Crossref
Eugènia Negredo, Pere Domingo, Núria Pérez-Álvarez, Mar Gutiérrez, Gracia Mateo, Jordi Puig, Roser Escrig, Patricia Echeverría, Anna Bonjoch & Bonaventura Clotet. (2014) Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). Journal of Antimicrobial Chemotherapy 69:12, pages 3368-3371.
Crossref
Crossref
Juliet Compston. (2014) Osteoporosis and Fracture Risk Associated with HIV Infection and Treatment. Endocrinology and Metabolism Clinics of North America 43:3, pages 769-780.
Crossref
Crossref
F. Raffi, A. L. Pozniak & M. A. Wainberg. (2014) Has the time come to abandon efavirenz for first-line antiretroviral therapy?. Journal of Antimicrobial Chemotherapy 69:7, pages 1742-1747.
Crossref
Crossref
Esteban Martínez, Esteban Jódar Gimeno, Rebeca Reyes García, Pedro Carpintero, José Luis Casado, Javier del Pino Montes, Pere Domingo Pedrol, Vicente Estrada, Jorge Maalouf, Eugenia Negredo, Antonio Ocampo & Manuel Muñoz-Torres. (2014) Documento de consenso: Recomendaciones para el manejo de la enfermedad ósea metabólica en pacientes con virus de la inmunodeficiencia humana. Enfermedades Infecciosas y Microbiología Clínica 32:4, pages 250-258.
Crossref
Crossref
David A. Cooper, Jayvant Heera, Prudence Ive, Mariette Botes, Edwin Dejesus, Robert Burnside, Nathan Clumeck, Sharon Walmsley, Adriano Lazzarin, Geoffrey Mukwaya, Michael Saag & Elna van Der Ryst. (2014) Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1. AIDS 28:5, pages 717-725.
Crossref
Crossref
David A Wohl, Chloe Orkin, Manuela Doroana, José H Pilotto, Somnuek Sungkanuparph, Patrick Yeni, Simon Vanveggel, Henri Deckx & Katia Boven. (2013) Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo). Antiviral Therapy 19:2, pages 191-200.
Crossref
Crossref
Tahereh Ghaziani. (2014) Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. World Journal of Gastroenterology 20:39, pages 14142.
Crossref
Crossref
Stephen G Holt, David M Gracey, Miriam T Levy, David W Mudge, Ashley B Irish, Rowan G Walker, Richard Baer, Jacob Sevastos, Riaz Abbas & Mark A Boyd. (2014) A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Research and Therapy 11:1, pages 35.
Crossref
Crossref
L. Wang, A. P. Kourtis, S. Ellington, J. Legardy-Williams & M. Bulterys. (2013) Safety of Tenofovir During Pregnancy for the Mother and Fetus: A Systematic Review. Clinical Infectious Diseases 57:12, pages 1773-1781.
Crossref
Crossref
Lixia Zhang, Yuanbo Su, Evelyn Hsieh, Weibo Xia, Jing Xie, Yang Han, Ying Cao, Yanling Li, Xiaojing Song, Ting Zhu, Taisheng Li & Wei Yu. (2013) Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy –a prospective observational study. BMC Musculoskeletal Disorders 14:1.
Crossref
Crossref
. (2013) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013). Enfermedades Infecciosas y Microbiología Clínica 31:9, pages 602.e1-602.e98.
Crossref
Crossref
Graeme J Moyle, Hans-Jürgen Stellbrink, Juliet Compston, Chloe Orkin, José R Arribas, Pere Domingo, Catherine Granier, Helen Pearce, Sangeeta Sedani & Martin Gartland. (2013) 96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study. Antiviral Therapy 18:7, pages 905-913.
Crossref
Crossref
Lisa A. Grohskopf, Kata L. Chillag, Roman Gvetadze, Albert Y. Liu, Melanie Thompson, Kenneth H. Mayer, Brandi M. Collins, Sonal R. Pathak, Brandon O'Hara, Marta L. Ackers, Charles E. Rose, Robert M. Grant, Lynn A. Paxton & Susan P. Buchbinder. (2013) Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 64:1, pages 79-86.
Crossref
Crossref
Patrick Marcellin & Tarik Asselah. (2013) Long-term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal. Journal of Gastroenterology and Hepatology 28:6, pages 912-923.
Crossref
Crossref
Christine Njuguna, Catherine Orrell, Richard Kaplan, Linda-Gail Bekker, Robin Wood & Stephen D. Lawn. (2013) Rates of Switching Antiretroviral Drugs in a Primary Care Service in South Africa before and after Introduction of Tenofovir. PLoS ONE 8:5, pages e63596.
Crossref
Crossref
S. A. Diop, L. Fortes-Déguénonvo, M. Seydi, A. B. Dieng, C. D. Basse, N. M. Manga, N. M. Dia, G. Ndaw, C. T. Ndour, M. Soumaré, B. M. Diop & P. S. Sow. (2012) Efficacité et tolérance de l’association ténofovir-lamivudine-éfavirenz chez les patients VIH-1 à la clinique des maladies infectieuses du CHNU de Fann à DakarEfficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar. Bulletin de la Société de pathologie exotique 106:1, pages 22-26.
Crossref
Crossref
. (2013) Antiretroviral Preexposure Prophylaxis for HIV Prevention. New England Journal of Medicine 368:1, pages 82-84.
Crossref
Crossref
Michael T. Yin, Michelle A. Kendall, Xingye Wu, Katherine Tassiopoulos, Marc Hochberg, Jeannie S. Huang, Marshall J. Glesby, Hector Bolivar & Grace A. McComsey. (2012) Fractures after antiretroviral initiation. AIDS 26:17, pages 2175-2184.
Crossref
Crossref
Pedro Cahn. (2012) Rilpivirine in the treatment of HIV infection: evidence from the ECHO and THRIVE studies. Clinical Investigation 2:11, pages 1133-1144.
Crossref
Crossref
Georg Behrens, Renato Maserati, Armin Rieger, Pere Domingo, Florian Abel, Hui Wang & Gill Pearce. (2012) Switching to Tenofovir/Emtricitabine from Abacavir/ Lamivudine in HIV-Infected Adults with Raised Cholesterol: Effect on Lipid Profiles. Antiviral Therapy 17:6, pages 1011-1020.
Crossref
Crossref
K. Mulligan, D. R. Harris, P. Emmanuel, R. A. Fielding, C. Worrell, B. G. Kapogiannis, D. Monte, J. Sleasman, C. M. Wilson & G. M. Aldrovandi. (2012) Low Bone Mass in Behaviorally HIV-Infected Young Men on Antiretroviral Therapy: Adolescent Trials Network Study 021B. Clinical Infectious Diseases 55:3, pages 461-468.
Crossref
Crossref
Linda M. Mundy, Ada O. Youk, Grace A. McComsey & Steve J. Bowlin. (2012) Overall benefit of antiretroviral treatment on the risk of fracture in HIV. AIDS 26:9, pages 1073-1082.
Crossref
Crossref
. (2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). Enfermedades Infecciosas y Microbiología Clínica 30:6, pages e1-e89.
Crossref
Crossref
Rik Schrijvers & Zeger Debyser. (2012) Quad's in it for antiretroviral therapy?. The Lancet 379:9835, pages 2403-2405.
Crossref
Crossref
Edwin DeJesus, Jürgen K Rockstroh, Keith Henry, Jean-Michel Molina, Joseph Gathe, Srinivasan Ramanathan, Xuelian Wei, Kitty Yale, Javier Szwarcberg, Kirsten White, Andrew K Cheng & Brian P Kearney. (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet 379:9835, pages 2429-2438.
Crossref
Crossref
Mark J Bolland, Andrew Grey, Anne M Horne, Simon E Briggs, Mark G Thomas, Rod B Ellis‐Pegler, Greg D Gamble & Ian R Reid. (2012) Stable bone mineral density over 6 years in HIV‐infected men treated with highly active antiretroviral therapy (HAART). Clinical Endocrinology 76:5, pages 643-648.
Crossref
Crossref
Alyson N. Fox & Norah A. Terrault. (2012) The option of HBIG-free prophylaxis against recurrent HBV. Journal of Hepatology 56:5, pages 1189-1197.
Crossref
Crossref
Garima Kumari & Ramendra K. Singh. (2012) Highly Active Antiretroviral Therapy for treatment of HIV/AIDS patients: Current status and future prospects and the Indian scenario. HIV & AIDS Review 11:1, pages 5-14.
Crossref
Crossref
Amandine Cournil, Sabrina Eymard-Duvernay, Assane Diouf, Claire Moquet, Julie Coutherut, Ndèye Fatou Ngom Gueye, Cécile Cames, Bernard Taverne, Kirsten Bork, Papa Salif Sow & Eric Delaporte. (2012) Reduced Quantitative Ultrasound Bone Mineral Density in HIV-Infected Patients on Antiretroviral Therapy in Senegal. PLoS ONE 7:2, pages e31726.
Crossref
Crossref
Koen K.A. Van Rompay. (2012) The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies. AIDS Research and Human Retroviruses 28:1, pages 16-35.
Crossref
Crossref
David Nolan, Simon Mallal & Peter Reiss. 2012. Sande's HIV/AIDS Medicine. Sande's HIV/AIDS Medicine
177
191
.
Vicente Estrada, Paloma Geijo, Manuel Fuentes-Ferrer, María Luisa García Alcalde, María Rodrigo, María José Galindo, Agustín Muñoz, Pere Domingo, Esteve Ribera, Jaime Cosín, Pompeyo Viciana, Fernando Lozano, Alberto Terrón, Antonio Vergara, Ramón Teira, Josefa Muñoz-Sánchez, Bernardino Roca, Trinitario Sánchez, José López-Aldeguer, Elisabeth Deig, Francisco Vidal, Enric Pedrol, Manuel Castaño-Carracedo, Teresa Puig, Myriam Garrido & Ignacio Suárez-Lozano. (2011) Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort. BMC Women's Health 11:1.
Crossref
Crossref
Alessandra Viganò, Stefano Mora, Vania Giacomet, Sara Stucchi, Valeria Manfredini, Clara Gabiano, Filippo Salvini, Monica Cellini, Enrica Tamburrini, Maria Puzzovio & Gian Vincenzo Zuccotti. (2011)
In utero
exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers
. Antiviral Therapy 16:8, pages 1259-1266.
Crossref
Crossref
Anjali Sharma, Hillel W. Cohen, Ruth Freeman, Nanette Santoro & Ellie E. Schoenbaum. (2011) Prospective evaluation of bone mineral density among middle-aged HIV-infected and uninfected women: Association between methadone use and bone loss. Maturitas 70:3, pages 295-301.
Crossref
Crossref
Albert Y. Liu, Eric Vittinghoff, Deborah E. Sellmeyer, Risha Irvin, Kathleen Mulligan, Kenneth Mayer, Melanie Thompson, Robert Grant, Sonal Pathak, Brandon O'Hara, Roman Gvetadze, Kata Chillag, Lisa Grohskopf & Susan P. Buchbinder. (2011) Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco. PLoS ONE 6:8, pages e23688.
Crossref
Crossref
G. A. McComsey, D. Kitch, P. E. Sax, P. Tebas, C. Tierney, N. C. Jahed, L. Myers, K. Melbourne, B. Ha & E. S. Daar. (2011) Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s. Clinical Infectious Diseases 53:2, pages 185-196.
Crossref
Crossref
Grace A. McComsey, Douglas Kitch, Eric S. Daar, Camlin Tierney, Nasreen C. Jahed, Pablo Tebas, Laurie Myers, Kathleen Melbourne, Belinda Ha & Paul E. Sax. (2011) Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. The Journal of Infectious Diseases 203:12, pages 1791-1801.
Crossref
Crossref
Frank A Post, Eugene V McCloskey, Juliet E Compston, Christine A Bowman, Phillip E Hay, Margaret A Johnson, Patrick WG Mallon, Barry S Peters, Amanda Samarawickrama & Gareth Tudor-Williams. (2011) Prevention of bone loss and management of fracture risk in HIV-infected individuals: case studies and recommendations for different patient subgroups. Future Virology 6:6, pages 769-782.
Crossref
Crossref
Mark J Bolland & Andrew Grey. (2011) HIV and low bone density: Responsible party, or guilty by association?. IBMS BoneKEy 8:1, pages 7-15.
Crossref
Crossref
Emma D. Deeks & Caroline M. Perry. (2010) Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Atripla®). Drugs 70:17, pages 2315-2338.
Crossref
Crossref
Michael T Yin, Qiuhu Shi, Donald R Hoover, Kathryn Anastos, Anjali Sharma, Mary Young, Alexandra Levine, Mardge H Cohen, Elizabeth Shane, Elizabeth T Golub & Phyllis C Tien. (2010) Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 24:17, pages 2679-2686.
Crossref
Crossref
Panel de expertos de Gesida & Plan Nacional sobre el Sida. (2010) Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010). Enfermedades Infecciosas y Microbiología Clínica 28:6, pages 362.e1-362.e91.
Crossref
Crossref
R. B. Takkenberg, C. J. Weegink, H. L. Zaaijer & H. W. Reesink. (2010) New developments in antiviral therapy for chronic hepatitis B. Vox Sanguinis 98:4, pages 481-494.
Crossref
Crossref
Érico Higino de Carvalho, Thais Gelenske, Francisco Bandeira & Maria da Fátima Pessoa Militão de Albuquerque. (2010) Bone mineral density in HIV-infected women taking antiretroviral therapy: a systematic review. Arquivos Brasileiros de Endocrinologia & Metabologia 54:2, pages 133-142.
Crossref
Crossref
Michael T. Yin, Don J. McMahon, David C. Ferris, Chiyuan A. Zhang, Aimee Shu, Ronald Staron, Ivelisse Colon, Jeffrey Laurence, Jay F. Dobkin, Scott M. Hammer & Elizabeth Shane. (2010) Low Bone Mass and High Bone Turnover in Postmenopausal Human Immunodeficiency Virus-Infected Women. The Journal of Clinical Endocrinology & Metabolism 95:2, pages 620-629.
Crossref
Crossref
Michael T Yin, Dalian Lu, Serge Cremers, Phyllis C Tien, Mardge H Cohen, Qiuhu Shi, Elizabeth Shane, Elizabeth T Golub & Kathryn Anastos. (2010) Short-Term Bone Loss in HIV-Infected Premenopausal Women. JAIDS Journal of Acquired Immune Deficiency Syndromes 53:2, pages 202-208.
Crossref
Crossref
Youcef Mehellou & Erik De Clercq. (2009) Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?. Journal of Medicinal Chemistry 53:2, pages 521-538.
Crossref
Crossref
José A. Esté & Tomas Cihlar. (2010) Current status and challenges of antiretroviral research and therapy. Antiviral Research 85:1, pages 25-33.
Crossref
Crossref
Tomas Cihlar & Adrian S. Ray. (2010) Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Research 85:1, pages 39-58.
Crossref
Crossref
Koen K.A. Van Rompay. (2010) Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Research 85:1, pages 159-175.
Crossref
Crossref
E. Pollock, A.-E. Klotsas, J. Compston & E. Gkrania-Klotsas. (2009) Bone health in HIV infection. British Medical Bulletin 92:1, pages 123-133.
Crossref
Crossref
F. Maggiolo. (2009) Efavirenz: a decade of clinical experience in the treatment of HIV. Journal of Antimicrobial Chemotherapy 64:5, pages 910-928.
Crossref
Crossref
John A Bartlett & John F Shao. (2009) Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. The Lancet Infectious Diseases 9:10, pages 637-649.
Crossref
Crossref
P.-M. Girard, A. Cabie, C. Michelet, R. Verdon, C. Katlama, P. Mercie, L. Morand-Joubert, P. Petour, F. Monchecourt, G. Chene & A. Trylesinski. (2009) A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients. Journal of Antimicrobial Chemotherapy 64:1, pages 126-134.
Crossref
Crossref
A. Carrero & P. Ryan. (2009) Tenofovir y enfermedad ósea en pacientes infectados por el VIH. Revista Española de Enfermedades Metabólicas Óseas 18:3, pages 56-62.
Crossref
Crossref
Edwin DeJesus, Benjamin Young, Javier O Morales-Ramirez, Louis Sloan, Douglas J Ward, John F Flaherty, Ramin Ebrahimi, Jen-Fue Maa, Karen Reilly, Janet Ecker, Damian McColl, Daniel Seekins & Awny Farajallah. (2009) Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:2, pages 163-174.
Crossref
Crossref
Robert J. Fontana. (2009) Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49:S5, pages S185-S195.
Crossref
Crossref
Nils Venhoff & Ulrich Andreas Walker. (2009) Pathogenesis of bone disorders in HIV infection. International Journal of Clinical Rheumatology 4:2, pages 147-159.
Crossref
Crossref
TN Kakuda, M Schöller-Gyüre, G De Smedt, G Beets, F Aharchi, MP Peeters, K Vandermeulen, BJ Woodfall & RMW Hoetelmans. (2009) Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Medicine 10:3, pages 173-181.
Crossref
Crossref
Jason Faulhaber & Judith A. Aberg. 2009. Palliative Medicine. Palliative Medicine
1172
1182
.
Stefan Mauss, Florian Berger, Dieter Kuschak, Julia Henke, Petra Hegener, Eva Wolf, Stephan Schauseil & Guenther Schmutz. (2008) Cystatin C as a Marker of Renal Function is Affected by HIV Replication Leading to an Underestimation of Kidney Function in HIV Patients. Antiviral Therapy 13:8, pages 1091-1095.
Crossref
Crossref
Christoph A Fux, Andri Rauch, Mathew Simcock, Heiner C Bucher, Bernard Hirschel, Milos Opravil, Pietro Vernazza, Matthias Cavassini, Enos Bernasconi, Luigia Elzi & Hansjakob Furrer. (2008) Tenofovir use is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy 13:8, pages 1077-1082.
Crossref
Crossref
Michael T YinElizabeth ShaneKathryn Anastos. (2008) Clinical significance of HIV-associated bone loss: when and how to intervene. Future HIV Therapy 2:5, pages 465-478.
Crossref
Crossref
Koen K. A. Van Rompay, Lucie Durand-Gasselin, Laurie L. Brignolo, Adrian S. Ray, Kristina Abel, Tomas Cihlar, Abigail Spinner, Christopher Jerome, Joseph Moore, Brian P. Kearney, Marta L. Marthas, Hans Reiser & Norbert Bischofberger. (2008) Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological Effects. Antimicrobial Agents and Chemotherapy 52:9, pages 3144-3160.
Crossref
Crossref
A. Pozniak. (2008) Tenofovir: what have over 1 million years of patient experience taught us?. International Journal of Clinical Practice 62:8, pages 1285-1293.
Crossref
Crossref
C. Duvivier, J. Ghosn, L. Assoumou, C. Soulie, G. Peytavin, V. Calvez, M. A. Genin, J.-M. Molina, O. Bouchaud, C. Katlama & D. Costagliola. (2008) Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. Journal of Antimicrobial Chemotherapy 62:4, pages 797-808.
Crossref
Crossref
Guillermina Barril Cuadrado & Ignacio de los Santos Gil. (2008) Tratamiento de la toxicidad renal en el paciente positivo al virus de la inmunodeficiencia humana. Qué medir, cómo medirlo y con qué frecuencia. Enfermedades Infecciosas y Microbiología Clínica 26, pages 55-61.
Crossref
Crossref
Celia Miralles Álvarez. (2008) ¿Son iguales todas las combinaciones de análogos?. Enfermedades Infecciosas y Microbiología Clínica 26, pages 38-44.
Crossref
Crossref
Peter Vestergaard. (2007) Adverse Effects of Drugs on Bone and Calcium Metabolism/Physiology. Clinical Reviews in Bone and Mineral Metabolism 6:1-2, pages 1-16.
Crossref
Crossref
Sanjay Pujari, Ameet Dravid, Nikhil Gupte, Kedar Joshix & Vivek Bele. (2008) Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India. Journal of the International AIDS Society 10:1, pages 196-196.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:3.
Crossref
Crossref
Jose R Arribas, Anton L Pozniak, Joel E Gallant, Edwin DeJesus, Brian Gazzard, Rafael E Campo, Shan-Shan Chen, Damian McColl, Charles B Holmes, Jeffrey Enejosa, John J Toole & Andrew K Cheng. (2008) Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 47:1, pages 74-78.
Crossref
Crossref